104319-02-0 Usage
Description
(R)-(-)-9-acetyl-9-acetamido-6,11-dihydroxy-7,8,9,10-tetrahydro-5,12-naphthacenedione, also known as (R)-Epirubicin, is a synthetic anthracycline antibiotic and antineoplastic agent. It is characterized by its potent cytotoxic properties and is primarily used in the treatment of various types of cancer. (R)-(-)-9-acetyl-9-acetamido-6,11-dihydroxy-7,8,9,10-tetrahydro-5,12-naphthacenedione works by inhibiting the replication of DNA and RNA, which ultimately leads to the destruction of cancer cells.
Uses
Used in Oncology:
(R)-Epirubicin is used as a chemotherapy agent for the treatment of various types of cancer. It is particularly effective against breast, ovarian, and lung cancers, as well as non-Hodgkin's lymphomas. (R)-(-)-9-acetyl-9-acetamido-6,11-dihydroxy-7,8,9,10-tetrahydro-5,12-naphthacenedione's mechanism of action involves the inhibition of DNA and RNA replication, which disrupts the cancer cells' ability to proliferate and survive.
Used in Drug Development:
(R)-Epirubicin serves as a key component in the development of new chemotherapy regimens and drug combinations. Its potent cytotoxic effects make it a valuable tool in the fight against cancer, and ongoing research aims to minimize its side effects and improve its efficacy in combination with other treatments.
Used in Cancer Research:
As a potent cytotoxic agent, (R)-Epirubicin is also utilized in cancer research to study the mechanisms of action and resistance in various types of cancer. Understanding these processes can lead to the development of more targeted and effective therapies.
Despite its effectiveness, (R)-Epirubicin can cause significant side effects such as myelosuppression, gastrointestinal toxicity, and cardiotoxicity. These side effects may limit its use in certain patient populations, and ongoing research is focused on finding ways to mitigate these drawbacks while maintaining the drug's therapeutic benefits.
Check Digit Verification of cas no
The CAS Registry Mumber 104319-02-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,4,3,1 and 9 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 104319-02:
(8*1)+(7*0)+(6*4)+(5*3)+(4*1)+(3*9)+(2*0)+(1*2)=80
80 % 10 = 0
So 104319-02-0 is a valid CAS Registry Number.
104319-02-0Relevant articles and documents
Stereospecific Total Synthesis of 9-Aminoanthracyclines: (+)-9-Amino-9-deoxydaunomycin and Related Compounds
Ishizumi, Kikuo,Ohashi, Naohito,Tanno, Norihiko
, p. 4477 - 4485 (1987)
9-amino-9-deoxydaunomycin and related compounds, in which the hydroxyl group at the 9-position of daunomycin is replaced by an amino group, have been synthesized.Asymmetry was introduced into the synthetic sequence for the AB synthon by resolution of the intermediate amino ester or acetamido acid to afford (R)-(-)-2-acetyl-2-acetamido-5,8-dimethoxy-1,2,3,4-tetrahydronaphthalene, which was converted to the tetracyclic amido ketones by Friedel-Crafts acylation with phthalic anhydride or its 3-methoxy derivative.The resulting regioisomers 4- and 1-methoxy compounds were separed, after methylation and selective demethylation, by crystallization and preparative TLC.The required introduction of the C7-hydroxyl function proceeded stereosepcifically via a three-step reaction sequence involving formation of an oxazine compound.The silver trifluoromethane assisted glycosidation of the resulting aglycons with 2-deoxy-3,4-di-O-acetyl-D-erythro-pentopyranosyl bromide or N,O-bis(trifluoroacetyl)daunosaminyl chloride, followed by alkaline hydrolysis afforded the target glycosides.The work reported herein comprises an efficient, practical synthesis of 9-amino-9-deoxydaunomycin and its analogues with the same stereochemistry as in the naturally occurring anthracyclines.
